
UC San Diego Health Moores Cancer Center
@ucsdcancer
NCI-designated & Comprehensive. Research, clinical trials, transformative care, survivorship, public-policy changing discoveries. #DeliveringDiscoveries
ID: 1473383250995281922
https://moorescancercenter.ucsd.edu/ 21-12-2021 20:02:22
1,1K Tweet
3,3K Takipçi
238 Takip Edilen


Moores member Kathryn Ries Tringale will be sharing the latest insights into deep learning-based MRI therapeutics at #ASCO25 🔬 Join us at 11:15 a.m. for her presentation during a rapid oral abstract session focusing on developmental therapeutics! 🔗 Learn more about the session:


Don't miss Jona Hattangadi-Gluth, MD's presentation on artificial intelligence-enhanced radiation oncology! 💡🤖 Join Dr. Hattangadi-Gluth at 11:30 a.m. to learn more about recent research findings on AI usage in brain tumor treatment. 🔗 Add to your #ASCO25 agenda: meetings.asco.org/2025-asco-annu…



Join Rana McKay, MD, FASCO at 9:00 a.m. tomorrow for "Molecular and Clinical Characterization of KLK2 mRNA Expression in Prostate Cancer" 🧬 Dr. McKay will present new data exploring KLK2 as a potential biomarker in prostate cancer. Don’t miss this poster session on advancing precision


Don’t miss Rana McKay, MD, FASCO presenting new research from the PREDICT trial — a Phase 2, biomarker-driven study shaping the future of precision prostate cancer care. 🩺 Join us tomorrow from 9:00 a.m. to 12:00 p.m. to learn more about this groundbreaking research! 🔗 Add to your



Join DrBagrodia at 1:15 p.m. today for "Contemporary Management of Stage II Seminoma" 🎯 Dr. Bagrodia will be chairing this session on refining treatment strategies for metastatic germ-cell tumors—what’s changing, and what’s next for this disease. 🔗 Add to your #ASCO25


Excited to present our #ASCO25 poster on the RADICAL trial! 🎯 📌 Radium-223 + Cabozantinib vs Cabozantinib in RCC with bone mets 🎯 SSE-free survival, PFS, OS, QOL, liquid + tissue biomarkers 🧪 Trial OPEN for accrual! Thanks to Rana McKay, MD, FASCO for your mentorship and




MCC's Rana McKay, MD, FASCO will present early efficacy data from a trial exploring new treatment combinations for CRPC today at #ASCO25! 🌟 Join us at 9:45 a.m. to learn more about the COMRADE Trial, and how these findings will impact treatment of castration-resistant prostate cancer.


Meet Gene Yeo, PhD (Gene Yeo’s Lab at UC San Diego) — MCC's new Associate Director of Translational Science, in this #ResearcherSpotlight. A prominent leader across UC San Diego, Dr. Yeo shares his vision for this role, ongoing projects in his lab & where he sees his research heading over the next


Tune in to the latest episode of #TheScienceof Podcast as we explore the science of #CancerImmunology in triple negative breast cancer with Dr. Asona Lui of the UC San Diego Health Moores Cancer Center Radiation and Oncology Department and the students of the YMCA. Listen Here:shorturl.at/SvbZU


Honored to join the Board of Governors for Biocom California alongside such accomplished leaders in science & biotechnology. Excited to amplify the voices of academic cancer centers such as UC San Diego Health Moores Cancer Center & accelerate innovation that directly benefits patients! bit.ly/4kU4t4j


Had a rewarding fireside chat with Ambry Genetics CEO Tom Schoenherr after giving an address on germline genetics & cancer. Our goal: better identify who’s at risk and drive earlier detection. Grateful for partnerships fueling the future of precision medicine. #PrecisionMedicine


📢🔖Check out the insights of our brilliant UC San Diego Health Moores Cancer Center colleague Dr. Josh Demb in this important article from @businessinsider: "The taboo #ColonCancer symptom millennials are afraid to tell their doctors about" businessinsider.com/rectal-bleedin… #CRCSM #GetScreened

